Galectin-1

Bioxytran Releases Details on a Novel Carbohydrate Galectin Inhibitor designed to Eliminate COVID-19 in Patients

Retrieved on: 
Tuesday, March 31, 2020

Over the past decade there has been a strong body of evidence that indicates that Galectin-1 is implicated in viral pathogenesis.

Key Points: 
  • Over the past decade there has been a strong body of evidence that indicates that Galectin-1 is implicated in viral pathogenesis.
  • This galectin-1 treatment resulted in a survival benefit of the mice and indicated theoretical mechanisms of action (MOA) in humans.
  • The SARS virus has a galectin fold which in theory represents a binding spot on the virus for Bioxytrans galectin-1 inhibitor.
  • The journal articles provide a strong foundation that galectin-1 is implicated in COVID-19, said CEO David Platt of Bioxytran Inc. and co-author of Galectin.